ASLAN Pharmaceuticals Announces IND Submission for ASLAN003

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
35
ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period

- ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML - Positive interim Phase 2a data for ASLAN003 in AML was presented at the 2018 ASH Annual Meeting

SINGAPORE, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug (IND) application for ASLAN003. The company plans to evaluate ASLAN003 in the United States as part of an ongoing Phase 2 clinical trial. ASLAN003 is a potential treatment for acute myeloid leukaemia (AML), for which the FDA has previously granted Orphan Drug Designation.

ASLAN plans to enrol patients in the United States as part of a 20-patient expansion cohort for its ongoing trial, to be conducted once an optimum dose of ASLAN003 in AML has been established. In the United States, clinical sites have been selected and we expect the clinical trial to begin in the first half of 2019. Patients will also be enrolled in the expansion cohort in Singapore and Australia, where the Phase 2a clinical trial is ongoing.

Dr Carl Firth, CEO of ASLAN Pharmaceuticals, commented: “We’re excited to begin enrolling U.S. patients in our ASLAN003 Phase 2 clinical trial. We have been encouraged to see half of our evaluable patients recruited to date in our lower dose cohorts show signs of clinical activity. We expect our clinical trial activity in the United States and Asia to be supportive of potential approval in major markets and to fulfil our desire for a submission of a robust, comprehensive and compelling data package.”

ASLAN recently presented interim data from its Phase 2a clinical trial of ASLAN003 in AML at the 2018 American Society of Hematology (ASH) Annual Meeting. As of the 16 November 2018 data cut-off, 14 patients with AML ineligible for standard treatment (including relapsed, refractory and treatment naïve) had been enrolled in the multicentre dose optimisation study to evaluate ASLAN003 monotherapy administered as a 28-day cycle. Eight patients had received at least one post-treatment assessment at the cut-off date and were evaluable for efficacy. Of the eight evaluable patients, four patients showed clinical signs of efficacy: two patients (one in the 100mg once daily [QD] cohort and one in the 200mg QD cohort) exhibited evidence of myeloid differentiation and one patient in the 100mg QD cohort developed suspected differentiation syndrome. Overall, four patients had stable disease for more than three months with ASLAN003 being well tolerated by patients.

Media and IR contacts

Emma Thompson Spurwing Communications Tel: +65 6340 7287 Email: ASLAN@spurwingcomms.com   Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com

About ASLAN003 ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in acute myeloid leukaemia (AML). Licensed from Almirall in 2013, ASLAN has global rights for all non-topical and non- dermatological indications. AML is a cancer of the myeloid line of blood cells, characterised primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. ASLAN is conducting a Phase 2 clinical trial to develop ASLAN003 in AML and also exploring other solid tumour types where DHODH may be relevant.

About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.ASLANpharma.com .

Forward looking statements This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy, the Company’s plans to develop and commercialise its product candidates, the safety and efficacy of the Company’s product candidates, the Company’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company’s product candidates. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company’s U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s prospectus dated May 8, 2018 filed with the US Securities and Exchange Commission on such date. 

All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 38

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 60

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 17

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

INTCO Medical Surges Ahead with 40.6% Revenue Boost

Updated Category News Views 94

Eying Growth: INTCO Medical's Impressive Revenue Surge In today's corporate world, a 40.6% revenue jump over a single half-year isn't something to sneeze at. INTCO Medical, a heavyweight in the disposable glove industry, has done exactly that. The whispers out of Zibo, China, hint at a company that’s firing on all cylinders with $1.03 billion in their pockets for the...

Continue Reading
Taylor Davis Joins Pivot Point Consulting to Boost Client Success

Updated Category News Views 108

Pivot Point Consulting brought in a big player back then: Taylor Davis, the former President of KLAS Research. He wasn't just some guy; he founded the KLAS Arch Collaborative. This move was about shaking things up in healthcare consulting during tough times. Desks were buzzing over this power shift. In his past gig at KLAS, Davis was instrumental in creating standards...

Continue Reading
Entegris' Financial Highlights and Outlook for 2025

Updated Category News Views 971

Entegris Reports Strong Fourth Quarter Performance Entegris, Inc. (NASDAQ: ENTG) has recently released its financial results marking a robust conclusion to the fiscal year. The company's fourth-quarter performance surpassed projections for both revenue and non-GAAP earnings per share. CEO Insights on Market Dynamics Bertrand Loy, the President and CEO of Entegris,...

Continue Reading
Top Dividend Stocks Insiders Increased Their Investments In January

Updated Category News Views 109

Insider Purchasing Trends in Dividend Stocks January unveiled strong insider buying activity across various dividend-paying stocks, pointing to confidence in future growth. Leaders in this buying spree were notable companies including Lakeland Industries (NASDAQ: LAKE), York Water (NASDAQ: YORW), and RLI Corp (NYSE: RLI). Such movements may indicate these stocks are worth...

Continue Reading
FDA Approves Omvoh for Crohn's Disease: A New Era in Treatment

Updated Category News Views 515

FDA Approves Omvoh for Crohn's Disease Eli Lilly and Company (NYSE: LLY) proudly announces the FDA's approval of Omvoh (mirikizumab-mrkz), a groundbreaking treatment for adults suffering from moderately to severely active Crohn's disease. This marks a significant advancement, as Omvoh is now recognized for treating not just this debilitating condition but also ulcerative...

Continue Reading